Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV7P4N)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[3]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[3]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[4]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[5]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[6]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[7]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[1]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[1]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
2	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Prelude Therapeutics.
5	Clinical pipeline report, company report or official report of AbbVie.
6	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
7	Clinical pipeline report, company report or official report of Amgen.